The occurrence of immunological tolerance to inhibitors of factors VIIi and IX in hemophilia patients
Brakman, G.G.
Gematologiia i Transfuziologiia 38(2): 18-20
1993
ISSN/ISBN: 0234-5730 PMID: 8020714 Document Number: 407778
To abolish inhibitors, 40 out of 60 hemophiliacs (57 patients and 3 with hemophilia A and B, respectively) were treated according to the therapeutic scheme specified as Bonn protocol. A complete disappearance of the inhibitors was achieved in all the patients. These were followed up for 13 years during which they received on demand standard hemostatic treatment. No inhibitors have been registered so far.
Document emailed within 1 workday
Related Documents
Ewing, N.P. 1990: Induction of immune tolerance with factor VIIi concentrate in patients with hemophilia a and inhibitors Progress in Clinical and Biological Research 324: 59-68Iizuka, A.; Kuwashima, M.; Nagao, T. 1982: Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIIi or IX Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 45(5): 987-992
Landolfi, R.; de Cristofaro, R.; Lazzareschi, I.; Riccardi, R.; Mariani, G. 2000: Immune tolerance by intermittent factor VIIi boluses in two high responder hemophilia a patients Haematologica 85(10 Suppl): 73-74
Scharf, R.; Kucharski, W.; Lopaciuk, S.; Celińska, W.; Dmytrow, A.; Domański, K.; Gonet, S.; Miastkowski, Z.; Nowakowska, I.; Przybylski, A. 1991: Preliminary experience with achieving immune tolerance in patients with hemophilia a and circulating factor VIIi inhibitor Acta Haematologica Polonica 22(1): 92-99
Lottenberg, R.; Kentro, T.B.; Kitchens, C.S. 1987: Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy Archives of Internal Medicine 147(6): 1077-1081
DiMichele, D.; Kroner, B. 2000: The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis Haematologica 85(10 Suppl): 40
Kessler, C.M.; Ludlam, C.A. 1993: The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group Seminars in Hematology 30(2 Suppl. 1): 22-27
Ambriz-Fernández, R.; Reyna-Fregoso, M.P.; Pizzuto-Chávez, J.; Rodríguez-Moyado, H.; Farfán-Canto, J.M.; Trueba-Christy, E.; Collazo-Jaloma, J. 1985: Kinetics of the inhibitor of factor VIII:C in patients with hemophilia A. a study of the cooperative group of hemophilia Archivos de Investigacion Medica 16(3): 225-235
Fijnvandraat, K.; Berntorp, E.; ten Cate, J.W.; Johnsson, H.; Peters, M.; Savidge, G.; Tengborn, L.; Spira, J.; Stahl, C. 1997: Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients Thrombosis and Haemostasis 77(2): 298-302
Mahasandana, C.; Patharathienskul, D.; Suvatte, V. 1993: Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management Southeast Asian Journal of Tropical Medicine and Public Health 24(Suppl 1): 106-112
Antonarakis, S.E.; Kazazian, H.H. 1990: The molecular basis of hemophilia A (factor VIII deficiency) in man; progress report from the Johns Hopkins University Hemophilia Project Progress in Clinical and Biological Research 324: 1-11
Antonarakis, S.E.; Kazazian, H.H. 1990: The molecular basis of hemophilia A (factor VIII deficiency) in man; progress report from the Johns Hopkins University Hemophilia Project Progress in Clinical and Biological Research 324: 1-11
Rup, B. 2003: Immunogenicity and immune tolerance coagulation Factors VIIi and IX Developments in Biologicals 112: 55-59
Lopaciuk, S.; Ziemski, J.M. 1979: Treatment of patients with hemophilia a having antibodies to factor VIIi Acta Haematologica Polonica 10(2): 115-122
Kunst, V.A.; Nováková, I.R.; Haanen, C. 1989: Cryoprecipitate should have preference over factor VIII concentrate in the treatment of patients with hemophilia A Nederlands Tijdschrift Voor Geneeskunde 133(23): 1163-1166
Walker, I.; Poon, M.C. 1992: Recombinant factor VIII concentrate. The MSAC, Canadian Hemophilia Society. Canadian Hemophilia Clinic Directors Group Lancet 339(8784): 61-62
Mauser-Bunschoten, E.P.; Damen, M.; Reesink, H.W.; Roosendaal, G.; Chamuleau, R.A.; van den Berg, H.M. 1996: Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C Annals of Internal Medicine 125(4): 297-299
Kätzel, R.; Kubel, M.; Scheel, H.; Wegner, H. 1978: Results of in vivo analysis of injected fibrinogen degradation products and factor VIIi in patients with hemophilia a Zeitschrift für die Gesamte Innere Medizin und ihre Grenzgebiete 33(15): 525-529
Takase, T.; Nishino, M.; Yasui, M.; Shima, M.; Yoshikawa, N.; Fukui, H. 1985: Multimeric composition of factor VIII-related protein following DDAVP infusion in normal subjects and patients with hemophilia a and von Willebrand's disease Nihon Ketsueki Gakkai Zasshi: Journal of Japan Haematological Society 48(7): 1571-1578
Green, D. 1994: Immunosuppression of patients with acquired factor VIIi inhibitors Seminars in Hematology 31(2 Suppl 4: 60-61